hiv vaccine

Janssen Pharmaceutical Companies of Johnson & Johnson, together with a consortium of global partners, have announced that an independent data review of the Phase 3 Mosaico study of Janssen’s investigational HIV vaccine regimen was not effective in preventing HIV infection among the study participants. The study will be discontinued and further analysis of the data will be conducted. They revealed no safety issues with the vaccine regimen were identified during the trial. The consortium of global partners